Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
A phase 2 trial of 64Cu-DOTA-AE105 in prostate cancer, run by Curasight, now recruiting.
Overview
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer is a phase 2 interventional study registered as NCT06474806 by Curasight, with 168 participants planned, started 2024-06-01 and due to reach its primary completion in 2027-01-30. Interventions recorded: 64Cu-DOTA-AE105.
Similar pages
not linked directly; found by shared links- TrialPSMA-PET to Guide Prostatectomy
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
- TrialCopper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Shares Copper-64, Prostate cancer and the tag pipeline.
- TrialInvestigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
- TrialThis Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
- TrialTest-retest Evaluation of [18F]F-AraG PET
Shares PET (positron emission tomography) and the tag pipeline.
- Trial64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Shares Copper-64, Prostate cancer and the tag pipeline.